The PARPi with the highest PARP trapping activity, talazoparib and niraparib, were found to be most effective in increasing the cytotoxicity of cisplatin in bladder cancer cells (Bhattacharjee et al., 2022). The gene discussed is PARP1; the disease is urinary bladder carcinoma.